|
Value-Driven All-in-One LED Design for Effortless Deployment in Everyday Spaces
BREA, Calif., Jan. 9, 2026 /PRNewswire/ -- ViewSonic Corp., a leading global provider of visual solutions, is expanding the LED display lineup with the launch of the LDE Series, pre-configured All-in-One Direct View LED Displays that integrate all power and control systems directly into the cabinet. This lighter, fully integrated design simplifies wall mounting and cabling, offering installers and system integrators a space-efficient, quick-to-deploy solution for a wider range of LED applications.
"In a fast-growing LED market often characterized by tightly integrated ecosystems, labor-intensive setup, and high entry barriers, ViewSonic continues to broaden its All-in-One dvLED portfolio to make large-format displays easier to deploy and operate," said Dean Tsai, General Manager of Pro AV Solutions Business Unit at ViewSonic. "The new LDE Series enables more system integrators and resellers – even those without extensive LED installation experience – to confidently offer solutions, expand their portfolios, and address a broader range of projects. This helps organizations modernize their visual environments, whether refreshing existing spaces or transitioning from LCD video wall to immersive, high-quality dvLED."
All-in-One Integration for Greater Accessibility
The LDE Series integrates power, control, and image stitching directly into the cabinet, eliminating the need for an external control box and significantly reducing system complexity. This integration results in an ultra-slim 52 mm profile that is up to 28% lighter than comparable models, reducing wall load and eliminating the need for additional wall reinforcement. This lightweight design is particularly beneficial for prestigious or historical properties.
Furthermore, the full integration enables energy efficiency with a true power-off design that minimizes unnecessary standby energy consumption compared to conventional LED models. A simplified cabling approach shortens setup time and prevents connection errors, while a cleaner mainboard layout facilitates easier installation and maintenance. Together, these features help reduce potential downtime and ensure smoother deployment with minimal disruption.
Simple, Stable, Secure for Everyday Operation
The LDE Series is available in 136- and 163-inch screen sizes with 1080p resolution, 600 nits of brightness, 1.5–1.88 mm pixel pitch, and a 99% screen-to-body ratio. These configurations deliver immersive yet cost-effective visual performance for mid-sized boardrooms, school common areas, and retail signage.
To ensure reliability in busy, public-facing spaces, the LDE Series features a Glue-on-Board (GOB) surface treatment with IP54 and IK06 ratings, helping protect the screen against impact, dust, and moisture while reducing maintenance needs over time. Furthermore, a streamlined operating system and Q-SYS-ready integration simplify control and monitoring, enabling IT and AV teams to manage displays more intuitively in day-to-day operations across corporate, education, and retail environments.
About ViewSonic
Founded in 1987 and headquartered in Brea, California, ViewSonic is a leading global provider of visual solutions for the education, business, and consumer markets, with a presence in over 100 countries. Driven by the mission to transform education, workplaces, and lives, the company delivers a unified ecosystem of innovative hardware, software, and services that integrates seamlessly with the platforms, tools, and partners customers trust. Its product portfolio includes monitors, projectors, interactive displays, LED displays, commercial displays, video conferencing systems, and industrial solutions. Complementing its hardware is a robust suite of software offerings—including myViewBoard, ClassSwift, TeamOne, Manager, and AirSync—featuring AI-powered tools for collaboration, device optimization, and management. By empowering creativity, collaboration, and lifelong learning, ViewSonic supports customers at every stage in achieving their business and sustainability goals, creating a lasting impact and helping people everywhere connect with purpose—and See the Difference. Learn more at www.viewsonic.com.
Value-Driven All-in-One LED Design for Effortless Deployment in Everyday Spaces
BREA, Calif., Jan. 9, 2026 /PRNewswire/ -- ViewSonic Corp., a leading global provider of visual solutions, is expanding the LED display lineup with the launch of the LDE Series, pre-configured All-in-One Direct View LED Displays that integrate all power and control systems directly into the cabinet. This lighter, fully integrated design simplifies wall mounting and cabling, offering installers and system integrators a space-efficient, quick-to-deploy solution for a wider range of LED applications.
"In a fast-growing LED market often characterized by tightly integrated ecosystems, labor-intensive setup, and high entry barriers, ViewSonic continues to broaden its All-in-One dvLED portfolio to make large-format displays easier to deploy and operate," said Dean Tsai, General Manager of Pro AV Solutions Business Unit at ViewSonic. "The new LDE Series enables more system integrators and resellers – even those without extensive LED installation experience – to confidently offer solutions, expand their portfolios, and address a broader range of projects. This helps organizations modernize their visual environments, whether refreshing existing spaces or transitioning from LCD video wall to immersive, high-quality dvLED."
All-in-One Integration for Greater Accessibility
The LDE Series integrates power, control, and image stitching directly into the cabinet, eliminating the need for an external control box and significantly reducing system complexity. This integration results in an ultra-slim 52 mm profile that is up to 28% lighter than comparable models, reducing wall load and eliminating the need for additional wall reinforcement. This lightweight design is particularly beneficial for prestigious or historical properties.
Furthermore, the full integration enables energy efficiency with a true power-off design that minimizes unnecessary standby energy consumption compared to conventional LED models. A simplified cabling approach shortens setup time and prevents connection errors, while a cleaner mainboard layout facilitates easier installation and maintenance. Together, these features help reduce potential downtime and ensure smoother deployment with minimal disruption.
Simple, Stable, Secure for Everyday Operation
The LDE Series is available in 136- and 163-inch screen sizes with 1080p resolution, 600 nits of brightness, 1.5–1.88 mm pixel pitch, and a 99% screen-to-body ratio. These configurations deliver immersive yet cost-effective visual performance for mid-sized boardrooms, school common areas, and retail signage.
To ensure reliability in busy, public-facing spaces, the LDE Series features a Glue-on-Board (GOB) surface treatment with IP54 and IK06 ratings, helping protect the screen against impact, dust, and moisture while reducing maintenance needs over time. Furthermore, a streamlined operating system and Q-SYS-ready integration simplify control and monitoring, enabling IT and AV teams to manage displays more intuitively in day-to-day operations across corporate, education, and retail environments.
About ViewSonic
Founded in 1987 and headquartered in Brea, California, ViewSonic is a leading global provider of visual solutions for the education, business, and consumer markets, with a presence in over 100 countries. Driven by the mission to transform education, workplaces, and lives, the company delivers a unified ecosystem of innovative hardware, software, and services that integrates seamlessly with the platforms, tools, and partners customers trust. Its product portfolio includes monitors, projectors, interactive displays, LED displays, commercial displays, video conferencing systems, and industrial solutions. Complementing its hardware is a robust suite of software offerings—including myViewBoard, ClassSwift, TeamOne, Manager, and AirSync—featuring AI-powered tools for collaboration, device optimization, and management. By empowering creativity, collaboration, and lifelong learning, ViewSonic supports customers at every stage in achieving their business and sustainability goals, creating a lasting impact and helping people everywhere connect with purpose—and See the Difference. Learn more at www.viewsonic.com.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
ViewSonic Launches Innovative LDE Series to Bring dvLED Experiences Within Reach
|
HONG KONG, Jan. 9, 2026 /PRNewswire/ -- Ribo Life Science Co., Ltd. ("Ribo" or the "Company", stock code: 06938.HK), a leading company in small interfering RNA (siRNA) therapeutics, today successfully listed on the Main Board of Hong Kong Stock Exchange, marking a significant milestone in the capitalization of Chinese biopharmaceutical enterprises in the siRNA field and injecting new momentum into the industry.
In its global offering, Ribo issued a total of 31,610,400 shares at an offer price of HKD 57.97 per share, raising gross proceeds of over 1.8 billion Hong Kong dollars, HKPO was over 100x oversubscribed, International Placing was 16.7x oversubscribed, reflecting strong global investor confidence in the value of the siRNA sector and the Company's capabilities. The IPO proceeds will provide solid financial support for the advancement of the Company's core business. In addition, the offering attracted 12 cornerstone investors, including Arc Avenue, Ivy Rock, Springs Capital, China Asset Management, Dacheng International and Dacheng Fund, and Taikang Life Insurance etc., demonstrating the strong confidence of leading institutions in the Company's long-term prospects.
Dr. Zicai Liang, Founder, Chairman and Chief Executive Officer of Ribo, commented: "Listing on the Hong Kong Stock Exchange represents a major milestone in Ribo's journey. We extend our sincere gratitude to global investors for their trust and support. Moving forward, we will leverage the international capital markets to accelerate the global clinical development and commercialization of siRNA therapeutics, further strengthen our technologies, deliver breakthrough therapies to patients worldwide while creating sustainable value for shareholders."
Proceeds from the offering will be allocated across four key areas: (1) Advancing global multicenter clinical trials for core products; (2) Supporting preclinical and clinical development of the pipeline; (3) Iterating and upgrading siRNA delivery and other technology platforms; (4) Replenishing operational capital and earmarking funds for routine corporate purposes.
Ribo has built a fully integrated R&D platform with independent intellectual property rights. Its innovative liver-targeting RiboGalSTARTM delivery technology has successfully advanced multiple products into Phase II clinical trials. The Company has established R&D centers in Suzhou, Beijing and Gothenburg, Sweden, and a global R&D network capable of supporting end-to-end drug development from discovery to global clinical trials.
The listing was jointly sponsored by China International Capital Corporation and Citigroup, which provided professional support for the Company's successful entry into the capital markets.
About Ribo Life Science
Suzhou Ribo Life Science Co., Ltd. (06938.HK) is a global biopharmaceutical company engaged in the development and commercialization of small interfering RNA (siRNA) therapeutics. Powered by its proprietary and innovative siRNA technology platforms, the Company has built a rich and differentiated pipeline targeting major disease areas including cardiovascular, metabolic, liver and kidney diseases. Ribo is committed to delivering revolutionary treatment solutions to patients worldwide through continuous innovation.
For more information, please visit: www.ribolia.com.
HONG KONG, Jan. 9, 2026 /PRNewswire/ -- Ribo Life Science Co., Ltd. ("Ribo" or the "Company", stock code: 06938.HK), a leading company in small interfering RNA (siRNA) therapeutics, today successfully listed on the Main Board of Hong Kong Stock Exchange, marking a significant milestone in the capitalization of Chinese biopharmaceutical enterprises in the siRNA field and injecting new momentum into the industry.
In its global offering, Ribo issued a total of 31,610,400 shares at an offer price of HKD 57.97 per share, raising gross proceeds of over 1.8 billion Hong Kong dollars, HKPO was over 100x oversubscribed, International Placing was 16.7x oversubscribed, reflecting strong global investor confidence in the value of the siRNA sector and the Company's capabilities. The IPO proceeds will provide solid financial support for the advancement of the Company's core business. In addition, the offering attracted 12 cornerstone investors, including Arc Avenue, Ivy Rock, Springs Capital, China Asset Management, Dacheng International and Dacheng Fund, and Taikang Life Insurance etc., demonstrating the strong confidence of leading institutions in the Company's long-term prospects.
Dr. Zicai Liang, Founder, Chairman and Chief Executive Officer of Ribo, commented: "Listing on the Hong Kong Stock Exchange represents a major milestone in Ribo's journey. We extend our sincere gratitude to global investors for their trust and support. Moving forward, we will leverage the international capital markets to accelerate the global clinical development and commercialization of siRNA therapeutics, further strengthen our technologies, deliver breakthrough therapies to patients worldwide while creating sustainable value for shareholders."
Proceeds from the offering will be allocated across four key areas: (1) Advancing global multicenter clinical trials for core products; (2) Supporting preclinical and clinical development of the pipeline; (3) Iterating and upgrading siRNA delivery and other technology platforms; (4) Replenishing operational capital and earmarking funds for routine corporate purposes.
Ribo has built a fully integrated R&D platform with independent intellectual property rights. Its innovative liver-targeting RiboGalSTARTM delivery technology has successfully advanced multiple products into Phase II clinical trials. The Company has established R&D centers in Suzhou, Beijing and Gothenburg, Sweden, and a global R&D network capable of supporting end-to-end drug development from discovery to global clinical trials.
The listing was jointly sponsored by China International Capital Corporation and Citigroup, which provided professional support for the Company's successful entry into the capital markets.
About Ribo Life Science
Suzhou Ribo Life Science Co., Ltd. (06938.HK) is a global biopharmaceutical company engaged in the development and commercialization of small interfering RNA (siRNA) therapeutics. Powered by its proprietary and innovative siRNA technology platforms, the Company has built a rich and differentiated pipeline targeting major disease areas including cardiovascular, metabolic, liver and kidney diseases. Ribo is committed to delivering revolutionary treatment solutions to patients worldwide through continuous innovation.
For more information, please visit: www.ribolia.com.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Ribo Life Science (06938.HK) Successfully Lists on the Main Board of the Hong Kong Stock Exchange
